beloflow 5 mg tabletki powlekane
belupo lijekovi i kozmetika d.d. - solifenacini succinas - tabletki powlekane - 5 mg
beloflow 10 mg tabletki powlekane
belupo lijekovi i kozmetika d.d. - solifenacini succinas - tabletki powlekane - 10 mg
moxifloxacin genoptim 400 mg tabletki powlekane
synoptis pharma sp. z o.o. - moxifloxacini hydrochloridum - tabletki powlekane - 400 mg
moxifloxacin msn 400 mg tabletki powlekane
vivanta generics s.r.o. - moxifloxacinum - tabletki powlekane - 400 mg
cisatracurium kalceks 2 mg/ml roztwór do wstrzykiwań / do infuzji
as kalceks - cisatracurium - roztwór do wstrzykiwań / do infuzji - 2 mg/ml
byfavo
paion deutschland gmbh - remimazolam besilate - Świadoma sedacja - psycholeptyki - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.
hydrocortison vuab 100 mg proszek do sporządzania roztworu do wstrzykiwań / do infuzji
vuab pharma a.s. - hydrocortisonum - proszek do sporządzania roztworu do wstrzykiwań / do infuzji - 100 mg
jayempi
nova laboratories ireland limited - azathioprine - odrzucenie wniosku - leki immunosupresyjne - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
anturin 5 mg tabletki powlekane
us pharmacia sp. z o.o. - solifenacini succinas - tabletki powlekane - 5 mg
chlorprothixen hasco 15 mg tabletka powlekana
przedsiębiorstwo produkcji farmaceutycznej hasco-lek s.a. - chlorprothixeni hydrochloridum - tabletka powlekana - 15 mg